We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -3.92% | 24.50 | 24.00 | 25.00 | 25.50 | 24.50 | 25.50 | 170,170 | 12:06:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Services, Nec | 3.4M | -46.22M | -0.4626 | -0.53 | 24.48M |
From Apr 2019 to Apr 2024
NEW YORK, March 2, 2020 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference taking place on March 1-4, 2020, at the Boston Marriott Copley Place in Boston, Massachusetts.
The conference brings together top institutional investors and leading companies operating in the Health Care space. James McCullough, CEO of RenalytixAI, will be presenting on Tuesday, March 3 at 8:40am - 9:10am EST in Dartmouth, located on the 3rd floor, breakout: Exeter, 3rd floor.
The presentation will be made available on the Company's website shortly after, which can be located here: https://renalytixai.com/investors/company-presentation/. No new material or trading information will be provided.
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.
View original content:http://www.prnewswire.com/news-releases/renalytixai-ceo-to-speak-at-the-40th-annual-cowen-health-care-conference-301014632.html
SOURCE RenalytixAI
Copyright 2020 PR Newswire
1 Year Renalytix Chart |
1 Month Renalytix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
